Kadmon (KDMN) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Kadmon (NYSE:KDMN) from a buy rating to a hold rating in a research report sent to investors on Saturday.

According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “

Several other analysts also recently issued reports on the company. ValuEngine upgraded Kadmon from a hold rating to a buy rating in a research note on Wednesday, November 7th. WBB Securities upgraded Kadmon from a sell rating to a hold rating and set a $2.90 price target for the company in a research note on Wednesday, October 17th. Finally, HC Wainwright restated a buy rating and issued a $25.00 price target on shares of Kadmon in a research note on Monday, November 12th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $11.13.

Shares of NYSE KDMN opened at $2.43 on Friday. The company has a quick ratio of 6.58, a current ratio of 6.64 and a debt-to-equity ratio of 0.32. Kadmon has a 12 month low of $1.88 and a 12 month high of $5.86. The company has a market cap of $276.04 million, a PE ratio of -1.71 and a beta of 2.75.

Kadmon (NYSE:KDMN) last issued its earnings results on Friday, November 9th. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.09. Kadmon had a negative return on equity of 253.82% and a negative net margin of 1,176.75%. The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.56 million. On average, research analysts expect that Kadmon will post -0.78 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. lifted its position in shares of Kadmon by 730.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 173,830 shares of the company’s stock valued at $694,000 after acquiring an additional 152,900 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Kadmon during the 2nd quarter valued at $148,000. Rhumbline Advisers bought a new stake in shares of Kadmon during the 2nd quarter valued at $256,000. Renaissance Technologies LLC bought a new stake in shares of Kadmon during the 2nd quarter valued at $1,026,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in shares of Kadmon during the 2nd quarter valued at $105,000. Hedge funds and other institutional investors own 71.17% of the company’s stock.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Story: What is a Stop Order?

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply